Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (5024)	7/29/1998 2:11:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 6136

Bill: Not enough analysts to follow companies, and therefore one shouldn't invest in low-priced bargains (good science, leveraged business plans)?? Yup, that's exactly the message that was delivered. A few questions...... Don't you think it's just a tad arrogant when a Freudenthal tells you that a share price can't move without the support of analysts, of those with vested interests? Can't you just feel the manipulation? Do you honestly believe that, if $20 worth of cash, patents and research is available for $4, nobody will buy it? Rick

To: billkirn who wrote (5024)	7/29/1998 2:18:00 PM
From: Peter Singleton	Respond to of 6136

Bill, << I think the reason behind this attitude is, not enough analyists to follow these companies and no matter how good, they will be invisible. There are too many companies and too few people to folow them. These guys also expect a serious consolidation of the biotech industry. Loosing perhaps 100 companies over the next few years>> You mean, there aren't enough priests available to interpret the scriptures for us. D*mn it, let's translate them into English, and read them ourselves! ugh!